Cardiogenic Shock Clinical Trial
Official title:
Epidemiology and Prognostic of the Acute Heart Failure in Northeast of France
EPICAL 2 (Epidemiology and prognostic of the Acute Heart Failure) is an epidemiological,
observational, prospective and multicenter study. This study includes at first an exhaustive
recording of the cases on a geographic area at East of France, then the recorded patients
are followed up in a cohort at least 3 years. This study follows the experiences of the
EPICAL study led by our team.
Main objective: To describe the characteristics of the patients affected by acute heart
failure and to identify prognostic factors, in particular related to care. More exactly :
- To describe the sociodemographic, clinical, biological and therapeutic characteristics
of the patients presenting an acute heart failure during hospitalisation and living at
East of France ;
- To study the short and medium-term morbi-mortality of these patients, and identify the
main factors determining the prognosis for survival ;
- To evaluate the prognostic impact of the intra and extra-hospital care ;
- To identify the evolution of the care's practices of the decompensated heart failure
since the EPICAL study (15 years) and their influence on the prognosis of the disease.
Secondary objective: to constitute a biological collection of serum, plasma and urine of
patients' sample presenting an acute heart failure.
Criteria of inclusion:
- Patients hospitalized for acute heart failure or developing an acute heart failure
during the hospitalisation in the intensive care, cardiology or geriatrics departments
of the hospitals of Northeast of France during one year
- Patients died in emergencies or during the transfer, with a diagnosis of acute heart
failure.
Acute heart failure includes decompensation of chronic heart failure, advanced stage of the
heart failure, acute oedema of the lung and cardiogenic shock. According to the data of
registers, the incidence of the acute heart failure in approximately 2,5 cases per 1000
adults per year, the expected sample size amounts to 2500 eligible patients over 1 year.
Data collection: the doctors declare the Acute Heart Failure of their departments. The
technicians of clinical research collect the data concerning the sociodemographic, clinical,
biological and therapeutic characteristics of the inclusive patients on arrival at the
hospital, during the hospitalisation and at the exit. The biological takings are made for
the patients having given their consent before the exit of the hospitalization. The patients
are followed up during 3 years.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03283995 -
Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
|
||
| Active, not recruiting |
NCT04325035 -
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
|
Phase 2 | |
| Active, not recruiting |
NCT05100836 -
SURPASS Impella 5.5 Study
|
||
| Not yet recruiting |
NCT05106491 -
Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients
|
N/A | |
| Completed |
NCT02301819 -
ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock
|
N/A | |
| Completed |
NCT01367743 -
Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock
|
Phase 4 | |
| Recruiting |
NCT05728359 -
Genomic Determinants of Outcome in Cardiogenic Shock
|
||
| Recruiting |
NCT05699005 -
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO
|
Phase 1 | |
| Not yet recruiting |
NCT06338345 -
Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients
|
N/A | |
| Completed |
NCT03436641 -
Microcirculation in Cardiogenic Shock
|
||
| Recruiting |
NCT03313687 -
SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
|
||
| Recruiting |
NCT05506449 -
The RECOVER IV Trial
|
N/A | |
| Completed |
NCT04144660 -
"Treatment Use of ECMO In Pregnancy or Peripartum Patient."
|
||
| Completed |
NCT04548739 -
Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
|
||
| Recruiting |
NCT04141410 -
Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
|
||
| Not yet recruiting |
NCT05879276 -
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
|
Phase 3 | |
| Enrolling by invitation |
NCT05570864 -
Score TO Predict SHOCK - STOP SHOCK
|
||
| Completed |
NCT02591771 -
Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock
|
Phase 2 | |
| Terminated |
NCT02279979 -
Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial
|
N/A | |
| Completed |
NCT01374867 -
CardShock Study and Registry
|
N/A |